title: Orthotopic liver transplantation: treatment of choice in cirrhotic patients with hepatocellular carcinoma?
authors.affiliation: Liver Transplant Unit, C.S.U. Bellvitge, University of Barcelona, Spain.
authors.forename: P
authors.initials: P
authors.lastname: Moreno
authors.forename: E
authors.initials: E
authors.lastname: Jaurrieta
authors.forename: J
authors.initials: J
authors.lastname: Figueras
authors.forename: C
authors.initials: C
authors.lastname: Benasco
authors.forename: A
authors.initials: A
authors.lastname: Rafecas
authors.forename: J
authors.initials: J
authors.lastname: Fabregat
authors.forename: J
authors.initials: J
authors.lastname: Torras
authors.forename: T
authors.initials: T
authors.lastname: Casanovas
authors.forename: L
authors.initials: L
authors.lastname: Casais
mesh_terms: D000704:Analysis of Variance; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000601:surgery*; D016461:Chemoembolization, Therapeutic; D004317:Doxorubicin / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D008113:Liver Neoplasms / Q000150:complications / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D016031:Liver Transplantation / Q000401:mortality; D009367:Neoplasm Staging; D011184:Postoperative Period; D011379:Prognosis; D012008:Recurrence; D015996:Survival Rate; D013997:Time Factors
chemical_list: D004317:Doxorubicin